LOS ANGELES and BERLIN, October 2, 2017 /PRNewswire/ --
EBS Technologies, developer
The non-invasive Eyetronic therapy aims at improving the field of vision in patients suffering from glaucoma and other conditions affecting the optic nerve. By applying gentle electrical pulses to the optic nerve cells responsible for vision, the therapy achieves a two-fold effect: neuroprotection, which prevents further cell degeneration; and neurorestoration, which reactivates nerve tissue, resulting in restored vision. The method is based on a proven mode-of-action and published clinical data. Eyetronic is the first and only treatment that has demonstrated to not only slow down disease progression, but to also restore vision in glaucoma, the leading cause for irreversible blindness in the world, affecting 70 million people globally.
New hope for patients suffering from glaucoma
The Eyetronic therapy consists of ten sessions of 70 to 90 minutes each, applied on ten consecutive working days. One of the first centers to introduce the innovative treatment is the Ophthalmology Clinic at Wittenbergplatz, Berlin, Germany. "The Eyetronic therapy allows us to offer patients that could not be helped with current methods a new painfree and low-risk treatment", says Prof. Dr. med. Carl Erb, glaucoma expert and medical director of the clinic. "Before starting the therapy, we examine our patients to determine whether there are still intact areas of their visual field. This is a crucial requirement for a positive therapy outcome."
More than 300 patients have been treated with the Eyetronic therapy in six German therapy centers over the last two years. Leveraging new funds of 3 million Euros that EBS Technologies has recently raised with Norgine Venture, the company will focus on driving international expansion and the set-up of a US clinical trial.
MedTech Innovator nomination proves strong innovation and growth potential
Nearly 600 companies from around the globe have applied to the MedTech Innovator's 2017 competition. The jury of industry leaders and other healthcare stakeholders has narrowed down the group to the Top 100, who then presented at one of 11 pitch events around the United States and in Dublin, Ireland. Following the pitch events, the list was then narrowed down further to the 50 companies that were invited to participate in the MedTech Innovator Showcase on September 26 and 27, including EBS Technologies as one of only three selected European companies.
"The nomination among the top 50 companies at the MedTech Innovator 2017 competition is a great recognition, underlining the innovative approach and the strong potential of the Eyetronic therapy," says Karl Schweitzer, CEO of EBS Technologies. "With a successful track record of more than 300 patients treated in Germany, we will now work on bringing the therapy to more patients around the globe to help them regain their vision."
About MedTech Innovator
MedTech Innovator is the industry's nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator 2017 features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.
To learn more about MedTech Innovator, visit https://medtechinnovator.org/
About EBS Technologies
EBS Technologies, based in Berlin, Germany, develops software and hardware for medical stimulation therapies. The company holds several patents in the EU, Japan and the USA and received CE mark based on the successful completion of a multicenter randomized controlled clinical trial. The system is approved for the treatment of visual field loss caused by neuropathies of the optic nerve.
More information on Eyetronic (formerly: EBS therapy) is available under www.eyetronic.com.
Watch our video on Eyetronic: https://www.youtube.com/watch?v=NW819Ga8uVw&feature=youtu.be
For more information, please contact: BSKOM Eva Birle Tel: +49-89-13-95-78-27-11 Email: [email protected]
Gall C, Schmidt S, Schittkowski MP, Antal A, Ambrus GG, Paulus W, et al. (2016) Alternating Current Stimulation for Vision Restoration after Optic Nerve Damage: A Randomized Clinical Trial. PLoS ONE 11(6): e0156134.
SOURCE EBS Technologies
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All